These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 18705896)

  • 1. Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
    Alexandrov AV; Alagona P
    Int J Stroke; 2008 Aug; 3(3):175-81. PubMed ID: 18705896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
    Gorelick P; Sechenova O; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiplatelet strategies in atherothrombosis and their indications.
    Fontana P; Reny JL
    Eur J Vasc Endovasc Surg; 2007 Jul; 34(1):10-7. PubMed ID: 17324592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy in ischemic stroke.
    Pongrácz E; Káposzta Z
    Expert Rev Neurother; 2005 Jul; 5(4):541-9. PubMed ID: 16026237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists.
    Fintel DJ
    Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Booth J; Topol EJ;
    Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy in populations at high risk of atherothrombosis.
    Faxon DP; Nesto RW
    J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
    Mak KH; Bhatt DL; Shao M; Hankey GJ; Easton JD; Fox KA; Topol EJ
    Am Heart J; 2009 Apr; 157(4):658-65. PubMed ID: 19332192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke.
    Cavendish JJ; Cramer SC; Graham GD
    Curr Med Res Opin; 2004 Nov; 20(11):1845-9. PubMed ID: 15537485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The approach to optimizing stroke care.
    Panagos PD
    Am J Emerg Med; 2008 Sep; 26(7):808-16. PubMed ID: 18774049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.